Safety of Receiving Anti-Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis.

ABSTRACT:

Importance

Compared with the operating room (OR), office-based intravitreal injection (IVI) is considered a more cost-effective and convenient approach, yet clinical outcomes of IVIs with anti-vascular endothelial growth factor (VEGF) agents in different settings (office-based vs OR) have not been systematically evaluated.

Objective

To evaluate the safety outcomes of IVI with anti-VEGF agents in the OR vs office-based setting.

Data sources

PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov were searched from inception to July 2020.

Study selection

Eligible studies reporting on patients who received IVIs with anti-VEGF drugs with a clearly stated injection setting of the office or OR.

Data extraction and synthesis

Two reviewers indep

SUBMITTER: Li T 

PROVIDER: S-EPMC8377608 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature